CORONA Remedies Ltd. Stock price: Live updates

₹1728.3

2.68% (45.1)

Market Cap

₹10,571 Cr.

P/E

57.19

Key Ratios

Edit Ratio's

Market cap

10,571 Cr

57.19

Prom Holding

69.00 %

ROE (%)

24.65

ROCE (%)

30.24

Div Yield (%)

0.58

Sales

1,350 Cr

OPM (%)

20.58 %

Debt to Equity

0.10

Institutions

9.27 %

Individual < 2 lac

0.69 %

No. of Shareholders

19,609

Edit Ratio's

About

CORONA Remedies Ltd. develops, manufactures, and markets prescription and OTC medicines across… Read more

Low

1337

52W Range

High

1949

Timeline

Key company specific updates

Company Timeline

Subscribe now for more updates

Custom financial statement

Edit rows

Forensics

9 Yes

Positive for this company

1 Neutral

Neutral for this company

5 No

Negative for this company

2 No Data

Insufficient data to analyse

Accounting & Shareholding

Other Income

Other income is not affecting ratios of the company
Pledge

Promoters have not pledged a significant portion of their holding
Retail Holding

Retail has been selling the stock which is usually a good time to buy
Revenue Recognition

Company is converting accounting profit to cash
Promoter Holding

Promoter has not sold any shares in the last 90 days
Depreciation Effect

Company is depreciating a lower percentage of assets. this is contributing to an increase in net profit
Contingent Liabilities

Unable to calculate due to limited data

Price & Performance

Capex vs ROCE

Company has maintained it roce despite making significant capex
ROE

Net profit margin is responsible for roe increase over last 10 years
Working Capital

Working capital of the company seems to be under control
Debt

Company should not have issues servicing its debt
Balance Sheet Strength

Balance sheet of the company is strong. it shouldnt have solvency or liquidity issues
Current vs Historic Valuation

Company is trading at a premium to 3yr historic valuations
Share price

Share price has increased over last 10 years but more due to rerating
Margin Stability

Margins of the company are volatile
ROCE Strength

Roce of the company is not consistently strong
Sales Growth

Unable to calculate due to limited data

Revenue mix

Location Wise Break-Up

Therapeutic Area Break-Up

Acute vs Chronic

Asset Break-Up - Geography Wise

Operational Metrics

R&D as a % of Total Sales (%)
Source

Peer Comparison

Corporate Actions

Consolidated

DATE

DETAILS

Show Less

FAQs on CORONA Remedies Ltd. Business

What does CORONA Remedies do?

Who are the competitors of CORONA Remedies?

Is CORONA Remedies financially stable compared to its competitors?

View FAQ's On Shareprice

Company Filing

	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Annual Report	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Earnings Release	Jan Feb May
Investor Presentation	Jan Feb May
Conference Call	Jan Feb May
Conference Call SummaryCon Call Summary Powered by Claude

Discussions & Analysis

Ideas Dashboard

Results

Timeline

Watchlist

Portfolio

Alerts

Stock Screener

Market

Raw Material

CORONA Remedies Ltd.

CORONA Remedies Ltd.

Key Ratios

About

Timeline

Company Timeline

Custom financial statement

Forensics

9 Yes

1 Neutral

5 No

2 No Data

Accounting & Shareholding

Other Income

Pledge

Retail Holding

Revenue Recognition

Promoter Holding

Depreciation Effect

Contingent Liabilities

Price & Performance

Capex vs ROCE

ROE

Working Capital

Debt

Balance Sheet Strength

Current vs Historic Valuation

Share price

Margin Stability

ROCE Strength

Sales Growth

Revenue mix

Location Wise Break-Up

UNLOCK PREMIUM

Therapeutic Area Break-Up

UNLOCK PREMIUM

Acute vs Chronic

UNLOCK PREMIUM

Asset Break-Up - Geography Wise

UNLOCK PREMIUM

Operational Metrics

Peer Comparison

Corporate Actions

FAQs on CORONA Remedies Ltd. Business

What does CORONA Remedies do?

Who are the competitors of CORONA Remedies?

Is CORONA Remedies financially stable compared to its competitors?

Company Filing

Discussions & Analysis

SIGN UP FOR FREE